To the editor, The recent article by Chen et al. [1] provided for highly stimulating reading. Valproic acid mitigates tumor growth in a number of systemic malignancies besides gliomas.
Similar effects are seen in prostate carcinomas. Valproic acid causes augmentation of p27 levels leading to cell cycle arrest in the cancerous cells [2] . The expression of androgen receptors by the malignant tumor is also decreased. At the same time E-cadherin expression is augmented markedly [3] . Angiogenesis is also inhibited at the same time thus decreasing tumor growth. Cyclin D1 expression is also attenuated at the same time, while cytokeratin-18 expression is increased [4] . This results in a decrease in tumor invasiveness as well as a decline in cancer cell migration. Valproic acid also has an augmenting effect on the radio-sensitivity of prostate carcinomas [5] . It mediates this effect via acetylated p53 dependent modulation of mitochondrial membrane potential in the cancerous cells. Similar effects have been seen in bladder carcinomas. It mediates its anti-neoplastic effect in bladder tumors by inhibiting histone deacetylase [6] . Simultaneous up-regulation of thrombospondin-1 expression is also seen in bladder carcinomas.
Similarly, valproic acid inhibits tumor growth in colorectal malignancies. These effects are especially seen when it is used in combination with IIF. The dual combination enhances Bax expression while Bcl-2 expression is markedly reduced [7] . TIMP-1 activity is also enhanced at the same time, while MMP2 activity is considerably reduced.
These effects are time dependent. The combination also markedly up-regulates the expression of RXRc. Histone deacetylase activity is also markedly reduced. Valproic acid also augments the radio-sensitivity of colon carcinomas. p53 plays a major role in this valproic acid mediated radio-sensitization. It is clear from the above examples that valproic acid may have significant tumor attenuating effects. There is an urgent need to fully as well as further evaluate these anti-neoplastic effects.
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